Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials.

特立帕肽 医学 德诺苏马布 唑来膦酸 骨质疏松症 骨矿物 内科学 股骨颈 随机对照试验 泌尿科 外科
作者
Weiyang Wang,L-H Chen,Wendy Ma,Ruxu You
出处
期刊:PubMed 卷期号:27 (17): 8253-8268
标识
DOI:10.26355/eurrev_202309_33586
摘要

This study aims to compare the efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of women with postmenopausal osteoporosis.Randomized controlled trials (RCTs) were searched in Medline, Embase, and Cochrane up to April 2022. Statistical analysis was performed using R 4.1.3 software, and quality evaluation was conducted using Review Manager 5.3.51 RCTs containing 39,095 patients met our selection criteria. The efficacy results indicated that teriparatide was more effective than ibandronic acid in reducing vertebral fractures [relative risk (RR) = 0.536; 95% confidence interval (CI) (0.266, 0.998)]. Denosumab [mean difference (MD) = -4.19; 95% CI (-8.03, -0.355)] and teriparatide [MD = 4.64; 95% CI (1.60, 7.72)] showed better efficacy than ibandronic acid in improving spine bone mineral density (BMD). Denosumab showed better efficacy than teriparatide in improving radius BMD [MD = -4.14; 95% CI (-6.72, -1.54)], hip bone mineral density (BMD) [MD = -2.01; 95% CI (-3.80, -0.162)], and one-third radius BMD [MD = -3.63; 95% CI (-7.04, -0.151)]. Denosumab was associated with the greatest benefit in increasing radius BMD [the surface under the cumulative ranking curve area (SUCRA) = 0.999], hip BMD [surface under the cumulative ranking curve area (SUCRA) = 0.979], femoral neck BMD (SUCRA = 0.971), one-third radius BMD (SUCRA = 0.994) and preventing vertebral fractures (SUCRA = 0.806). Teriparatide was associated with the greatest benefit in preventing non-vertebral fractures (SUCRA = 0.927) and improving spine BMD (SUCRA = 0.899). The safety results indicated that teriparatide was safer than zoledronic acid regarding the risk of adverse events [RR = 0.958; 95% CI (0.919, 0.988)]. Teriparatide was associated with the greatest benefit in preventing adverse events (SUCRA = 0.908) and serious adverse events (SUCRA = 0.813).Our current results suggested that when considering both safety and efficacy, denosumab or teriparatide might be a better choice for women with postmenopausal osteoporosis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
chihirovvvv完成签到,获得积分10
刚刚
内向映天完成签到 ,获得积分10
1秒前
一多完成签到 ,获得积分10
1秒前
小葫芦完成签到 ,获得积分10
1秒前
Cheung2121发布了新的文献求助10
2秒前
zzz发布了新的文献求助10
2秒前
小麦完成签到,获得积分10
4秒前
风中的非笑完成签到,获得积分10
4秒前
SICHEN发布了新的文献求助10
5秒前
大模型应助程公子采纳,获得10
6秒前
zhao完成签到,获得积分10
6秒前
旺仔同学发布了新的文献求助10
7秒前
RX信完成签到,获得积分10
8秒前
mumufan完成签到,获得积分10
8秒前
无花果应助晴云采纳,获得10
8秒前
啊标完成签到,获得积分10
8秒前
耕牛热完成签到,获得积分10
8秒前
bsn完成签到 ,获得积分10
9秒前
Akim应助乌拉拉采纳,获得10
10秒前
夏傥完成签到,获得积分10
11秒前
11秒前
彭博完成签到 ,获得积分10
12秒前
SICHEN完成签到,获得积分10
12秒前
韩_完成签到,获得积分10
13秒前
nnnnn完成签到 ,获得积分10
14秒前
鉨汏闫完成签到,获得积分10
14秒前
14秒前
mahliya完成签到,获得积分10
15秒前
耕牛热发布了新的文献求助10
15秒前
天天快乐应助zzz采纳,获得10
16秒前
整齐的白凡完成签到,获得积分10
16秒前
坐雨赏花完成签到 ,获得积分10
16秒前
查理fofo完成签到,获得积分10
18秒前
Shandongdaxiu完成签到 ,获得积分10
20秒前
丘比特应助旺仔同学采纳,获得10
20秒前
科研通AI2S应助旺仔同学采纳,获得10
20秒前
Jasper应助旺仔同学采纳,获得10
20秒前
量子星尘发布了新的文献求助10
20秒前
20秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038426
求助须知:如何正确求助?哪些是违规求助? 3576119
关于积分的说明 11374556
捐赠科研通 3305834
什么是DOI,文献DOI怎么找? 1819339
邀请新用户注册赠送积分活动 892678
科研通“疑难数据库(出版商)”最低求助积分说明 815029